US FDA perspective: getting back into high gear – driving cell and gene therapy forward through 2022 and beyond

Cell & Gene Therapy Insights 2021; 7(12), 1745–1751


Published: 20 December 2021
Peter Marks

Peter Marks, MD, PhD, is the director of the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration. The center is responsible for assuring the safety and effectiveness of biological products, including vaccines, allergenic products, blood and blood products, and cellular, tissue, and gene therapies.